Monopar Therapeutics Inc.
NASDAQ:MNPRBiotechnology
+$1.58 today
- Market cap
- $479.46M
- Beta
- 1.54
- P/E (TTM)
- -37.6
- EPS (TTM)
- -$1.76
Volume 0.10M
Average 0.17M
MNPR Total Assets
Everything the company owns or controls; equal to total liabilities plus equity.
Monopar Therapeutics Inc.NASDAQ: MNPR
Total Assets · Q1 FY2026 · quarter ended Mar 2026
Total assets rises 150.5% from a year ago
Total assets stood at $137.98M at the end of Q1 FY2026, up 150.5% from a year earlier and down 1.9% from the prior quarter. Over 3 fiscal years it compounded at +119.9% a year.
Context
- Total assets increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether total assets keeps rising in the next quarterly balance sheet after a +150.5% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Assets history
USD · from the balance sheet
- Latest · FY2025
- 140.72M USD
- Year-over-year change
- +133.4%
- 4-year CAGR
- +61.8%
| Period | Period end | Total Assets | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 140.72M | +133.4% |
| FY2024 | 2024-12-31 | 60.29M | +720.8% |
| FY2023 | 2023-12-31 | 7.35M | -44.5% |
| FY2022 | 2022-12-31 | 13.23M | -35.5% |
| FY2021 | 2021-12-31 | 20.52M | — |
Total Assets vs competitors
How MNPR compares with its peers on the latest reported figures
- Peers report in different currencies, so total assets is compared through growth and rates rather than absolute size.
- Its year-over-year change of +150.5% is the 2nd highest of 11, against a peer median of +2.0%.
- Over three fiscal years its annual growth of +119.9% compares with a peer median of -8.5%.
| Company | Period | Latest balance | YoY | 3-year CAGR |
|---|---|---|---|---|
| Sep 2026 | $1.18B USD | +196.1% | -18.9% | |
| Jun 2026 | $724.96M USD | -17.6% | +1.1% | |
| Mar 2026 | $652.4M USD | -26.2% | +20.5% | |
| Sep 2026 | $505.53M USD | +68.9% | +205.1% | |
| Mar 2026 | $291.5M USD | +7.0% | -13.0% | |
| Mar 2026 | $217.87M USD | -3.0% | -3.9% | |
| Mar 2026 | $205.17M USD | +56.1% | +3.2% | |
| Mar 2026 | $178.33M USD | +47.5% | -42.2% | |
| Mar 2026 | $137.98M USD | +150.5% | +119.9% | |
| Dec 2025 | €62.69M EUR | -43.6% | -32.9% | |
| Jun 2026 | $40.16M USD | -36.3% | -23.2% | |
| Peer median (excluding MNPR) | — | +2.0% | -8.5% | |
Competitors are the stored peer set for MNPR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Monopar Therapeutics Inc.
NASDAQ:MNPR
Intrinsic Alpha fair value
Locked
Current Price
$70.75
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.